General Information of Drug (ID: DM0UBI9)

Drug Name
N,N-diethyl-2-(1H-indol-3-yl)ethanamine Drug Info
Synonyms
Diethyltryptamine; N,N-Diethyltryptamine; 61-51-8; N,N-Diethyl-2-(1H-indol-3-yl)ethanamine; 3-(2-Diethylaminoethyl)indole; UNII-916E8V4S2V; INDOLE, 3-(2-(DIETHYLAMINO)ETHYL)-; BRN 0153320; D.E.T.; CHEMBL142936; DEA No. 7434; 916E8V4S2V; 1H-Indole-3-ethanamine, N,N-diethyl-; AC1L1LS6; Oprea1_105894; 5-22-10-00050 (Beilstein Handbook Reference); SCHEMBL517713; DTXSID9052763; CTK5B3364; LSSUMOWDTKZHHT-UHFFFAOYSA-N; ZINC1999162; BDBM50094676; STK368075; AKOS005444987; 1H-Indole-3-ethanamine,N,N-diethyl-; 63938-63-6 (mono-hydrochloride)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6090
CAS Number
CAS 61-51-8
TTD Drug ID
DM0UBI9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [2]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [3]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [4]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [5]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [4]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [6]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [7]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [3]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [8]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [1]

References

1 Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5.
2 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
3 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
4 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
5 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
6 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
7 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
8 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
9 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.